" When asked about the company's current or targeted ZMapp production capacity, he said that information would be proprietary."
Washington, Aug 7 - Mass production of an experimental drug given to two US aid workers with Ebola may take several months, the US manufacturer said Wednesday.

International attention turned to the experimental drug known as ZMapp, developed by San Diego-based Mapp Biopharmaceutical and manufactured by Owensboro-based Kentucky BioProcessing (KBP), Xinhua reported.

Nancy Writebol and Kent Brantly were diagnosed with Ebola while treating patients in Liberia, seemed to be improving after they were treated with the medication.

KBP is working closely with Mapp Biopharmaceutical, various government agencies, and other parties to increase production of ZMapp, KBP spokesman David Howard told Xinhua.

But this process will take several months, Howard said.

Howard said in an email that the company provided a limited amount of ZMapp to Emory University Hospital in Atlanta, where the two were being treated, after it received a request last week from the hospital.

However, the spokesman said he cannot comment nor confirm whether ZMapp has been administered to any patient.

When asked about the company's current or targeted ZMapp production capacity, he said that information would be proprietary.

Earlier, Mapp Biopharmaceutical said in a statement that ZMapp, a mixture of three monoclonal antibodies, was first identified as a drug candidate in January and has not yet been evaluated for safety in humans.


comments powered by Disqus
Read more on:
 

PERMALINK

http://www.nerve.in/news:2535002394125
You can quote the permanent link above for a direct link to the story. We do not archive or expire our news stories.


STORY OPTIONS
  Email this story to a friend
  XML feed for Americas


 
COPYRIGHTS INFORMATION
All rights reserved for news content. Reproduction, storage or redistribution of Nerve content and articles in any medium is strictly prohibited.
Contact Nerve Staff for any feedback, corrections and omissions in news stories.
 

All rights reserved for the news content. Reproduction, storage or redistribution of Nerve content and articles in any medium is strictly prohibited.